Menu
ncarol.com
  • Home
  • Books
  • Book Release
  • Business
  • Health
  • Music
  • Financial
  • Technology
  • Real Estate
ncarol.com

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
ncarol.com/10291348

Trending...
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance
  • Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - ncarol.com -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on ncarol.com
  • Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds
  • Allstream Energy Partners Announced as Official Media Partner for the 2nd Annual Permian Power Conference
  • Children's Book for Kids with Limb Differences Coming Soon!
  • CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
  • Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Las Vegas Headliner Don Barnhart Brings National Touring Comedy Show to Comedy Cabana
  • Nevada Boxing Hall of Fame Announces 14th Annual Induction Gala Weekend Honoring Classes of 2025 and 2026
  • Brosix Celebrates 20 Years of Private Team Messaging for Small and Mid-Sized Businesses
  • Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season
  • From Broken to Soaring Week 40
  • Finnish Political Satire Film Generates 10,000+ Cross-Platform Interactions Following Gandalf Parody Video Across TikTok, YouTube and Telegram
  • AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
  • 2026 Editorial Freelancers Association Conference Focuses on Building Sustainable Careers
  • netElastic Powers LigaT's High-Performance Broadband Expansion and IPv6 Modernization in Portugal
  • Raiku launches rkuSOL with Sanctum, Kamino, Loopscale and Exponent
  • Greenland Mines Ltd (N A S D A Q: GRML) Advances Strategic Growth Initiatives as Critical Minerals Demand Accelerates
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • $97.9 Million Q1 Revenue Growth Reinforces Transformation Into a Global AI & Digital Services Powerhouse: IQSTEL, Inc. (N A S D A Q: IQST)
  • Boston Industrial Solutions Launches Natron® 348 UV Inkjet Ink for Epson S3200 Print Heads
  • Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation
  • CAPHRA warns push for ASEAN vape ban ignores science
  • Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close
  • ENTOUCH Recognized on Inc.'s 2026 Best Workplaces List for the Third Year Running
  • P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
_catLbl0 _catLbl1

Popular on ncarol.com

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 169
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA - 112
  • T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence - 110
  • Federal indictments bring new scrutiny to SPLC practices and highlight the real‑world impact of its designations on nonprofit groups, including NCFM - 101
  • $29.8 Million Record Setting Q1 with Boosted Annual Guidance to $160 Million for Expanding Pre-Owned Boat Dealer: Off The Hook YS, Inc. N Y S E: OTH
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • SRK Collective Media Group Launches with a Modern Approach to Media, Authority Building, and Cultural Visibility
  • UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking
  • Robert J. Bradshaw's AYE is a Gripping Dual Reality Thriller Exploring the Increasingly Blurred Line Between Humanity and Technology

Similar on ncarol.com

  • CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
  • Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • Asheville Clinician Publishes New Hypothesis on Trigeminal Neuralgia in Elsevier Journal
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • Top 15 Mosquito-Infested Cities in Louisiana and East Texas Ranked for 2026 Mosquito Season
  • From Broken to Soaring Week 40
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • Boston Industrial Solutions Launches Natron® 348 UV Inkjet Ink for Epson S3200 Print Heads
  • CAPHRA warns push for ASEAN vape ban ignores science
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute